Associated Papers
Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing.
Carnero-Gregorio M et al.
Genes, 2026
The Correlation Among PD-L1 Expression and the Driver Genes Status in Malignant Pleural Effusion of Lung Adenocarcinoma.
Wang R et al.
Cytopathology : Official Journal of the British Society for Clinical Cytology, 2026
Histopathological associations, molecular findings and clinical outcomes of patients with non-small cell lung carcinoma with MET alterations: a 3-year retrospective Australian case series.
Li JJ et al.
Pathology, 2026
Targeting the Uncommon: A Case Report of Osimertinib Response in Advanced NSCLC Patient with Dual EGFR (E701fs and L702fs) Frameshift Deletions.
Wong AKQ et al.
Current Oncology (toronto, Ont.), 2026
Structural Studies of Fourth-Generation EGFR Inhibitors Reveal Insights into Selective T790M and C797S Targeting.
Damghani T et al.
Acs Medicinal Chemistry Letters, 2026
Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS).
Li A et al.
Nature Communications, 2026
Mutational landscape of lung adenocarcinoma in Czechia.
Ambrozkiewicz F et al.
Cancer Treatment and Research Communications, 2026
Efficacy of TKIs in non-small cell lung cancer with atypical EGFR p.L747P and p.L747S mutations.
Hu Q et al.
Frontiers in Oncology, 2026
Exon-level TP53 alterations and PD-L1 expression identified by pretreatment NGS stratify survival in EGFR-mutant non-small cell lung cancer treated with first-line osimertinib.
Kim SE et al.
Translational Lung Cancer Research, 2025
Deep Learning Predicts EGFR Mutation Status from Histology Images in Non-Small Cell Lung Cancer.
Park J et al.
Cancer Research Communications, 2025
Efficacy and safety with aumolertinib plus anlotinib for untreated EGFR-mutant NSCLC with brain metastases.
Chen J et al.
Npj Precision Oncology, 2025
Mining tumor and surrounding tissue information using artificial intelligence to predict responses to EGFR-targeted therapies and immunotherapy in lung cancer: a multicenter attribution analysis.
Zhang X et al.
La Radiologia Medica, 2025
MUTE-Seq: An Ultrasensitive Method for Detecting Low-Frequency Mutations in cfDNA With Engineered Advanced-Fidelity FnCas9.
Ye S et al.
Advanced Materials (deerfield Beach, Fla.), 2025
Clinical Application of In-House Comprehensive Genomic Profiling for Thoracic Cancer: Insights From a Japanese Hospital.
Takaoka H et al.
Cancer Science, 2025
Biological impact of chemotherapy during treatment with EGFR tyrosine kinase inhibitors for non-small cell lung cancer positive for EGFR activating mutations.
Iwama E et al.
Lung Cancer (amsterdam, Netherlands), 2025
Gene actionability according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) in No Specific Molecular Profile (NSMP) endometrial cancer.
Mastrantoni L et al.
Esmo Open, 2025
Anaplastic Lymphoma Kinase (ALK) Fusion as a Resistance Mechanism to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors With Complete Response After Osimertinib and Alectinib: A Case Report and Literature Review.
Cheung BMF et al.
Cureus, 2025
Long-term survival with adaptive dual-targeted therapy in an epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer patient with mesenchymal-epithelial transition (MET) amplification guided by minimal residual disease (MRD) assessments: a case report and literature review.
Liu X et al.
Translational Lung Cancer Research, 2025
Refining High-Risk EGFR-Mutant Lung Cancer Patients: The Role of Adjusted Variant Allele Frequency in First-Line Osimertinib Therapy.
Brambilla M et al.
Clinical Lung Cancer, 2025
AKT1 Functional Polymorphism (rs2494750) Influences Clinical Outcomes in Patients With Advanced Lung Cancer Treated With EGFR Inhibitors.
Choi SH et al.
Journal of Korean Medical Science, 2025
Spectrum of rare EGFR mutations in Indonesian lung adenocarcinoma: Findings from an 8-year analysis of 4,778 cases highlighting the need for advanced targeted therapies.
Heriyanto DS et al.
Narra J, 2025
Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-type Non-Small Cell Lung Cancer.
Trontzas IP et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
J-REGISTER: real-world study of Japanese patients with EGFR mutation-positive NSCLC treated with first-line afatinib.
Yamaguchi T et al.
Future Oncology (london, England), 2025
Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted Therapy.
Febres-Aldana CA et al.
Cancer Discovery, 2025
Racial Diversity and Co-Mutational Analysis of Biologically Relevant Alterations in EGFR Mutant Lung Cancers.
Gutta R et al.
Clinical Lung Cancer, 2025
Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA Workshop.
de Jager VD et al.
Ebiomedicine, 2025
Role of TP53 Mutations and EGFR Amplification in Risk Stratification of Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer With Immunohistochemistry as a Surrogate Marker.
Kim M et al.
Thoracic Cancer, 2025
The expanding role of the receptor tyrosine kinase MET as a therapeutic target in non-small cell lung cancer.
Sattler M et al.
Cell Reports. Medicine, 2025
The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC.
Oh SY et al.
Cell Reports. Medicine, 2025
Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer.
Shin JE et al.
Scientific Reports, 2025
Exploring practical experience with different treatments in NSCLC patients with MET-deregulated: a retrospective analysis from the real world.
Li M et al.
Bmc Pulmonary Medicine, 2025
MET Activation in Lung Cancer and Response to Targeted Therapies.
Okun SA et al.
Cancers, 2025
Actionable mutations in early-stage ovarian cancer according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT): a descriptive analysis on a large prospective cohort.
Camarda F et al.
Esmo Open, 2025
RNA-Based Next-Generation Sequencing Approach to Non-Small Cell Lung Cancer: A Single-Center Experience in Turkey.
Gorukmez O et al.
Human Heredity, 2025
ARID1A deficiency attenuates the response to EGFR-TKI treatment in lung adenocarcinoma.
Yang F et al.
Frontiers in Pharmacology, 2025
Genetic alterations affect immune contexture of non-small cell lung cancer: Ukrainian study.
Kozakov D et al.
Frontiers in Medicine, 2025
The prevalence and clinical significance of EGFR mutations in non-small cell lung cancer patients in Egypt: a screening study.
Helal AA et al.
Journal of the Egyptian National Cancer Institute, 2024
[Molecular pathology of lung adenocarcinomas, EGFR T790M resistance mutation study].
Kohánka A et al.
Magyar Onkologia, 2024
Different genetic profiles contribute to worse overall survival in patients with leptomeningeal metastases of non-small-cell lung cancer.
Tang X et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2024
Profiling Cell-Free DNA from Malignant Pleural Effusion for Oncogenic Driver Mutations in Patients with Treatment-Naive Stage IV Adenocarcinoma: A Multicenter Prospective Study.
Chang SC et al.
Molecular Diagnosis & Therapy, 2024
Detailed characterization of combination treatment with MET inhibitor plus EGFR inhibitor in EGFR-mutant and MET-amplified non-small cell lung cancer.
Lee Y et al.
Translational Lung Cancer Research, 2024
Prevalence of EGFR Mutations in Patients With Resected Stages I to III NSCLC: Results From the EARLY-EGFR Study.
Soo RA et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2024
Molecular characterization of Chinese patients with small bowel adenocarcinoma.
Jin B et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2024
Genomic and Immune Landscape Comparison of MET Exon 14 Skipping and MET-Amplified Non-small Cell Lung Cancer.
Minne RL et al.
Clinical Lung Cancer, 2024
Registry of Genetic Alterations of Taiwan Non-Small Cell Lung Cancer by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study-Taiwan Cooperative Oncology Group T1521.
Liao BC et al.
Jco Global Oncology, 2024
Patient-centric thresholding of Cobas® EGFR mutation Test v2 for surveillance of EGFR-mutated metastatic non-small cell lung cancer.
Claus J et al.
Scientific Reports, 2024
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.
Wu YL et al.
The Lancet. Oncology, 2024
The genomic landscape of lung cancer in never-smokers from the Women's Health Initiative.
Moorthi S et al.
Jci Insight, 2024